Leveraging Olink Proteomics® Proximity Extension Assay (PEA) technology, protein biomarker detection services from Azenta Life Sciences enable detection and quantification of circulating proteins to provide an in-depth, biological understanding of disease and drug response. Unlike traditional methods, this approach enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts. Processing is available for research use only (RUO) or can be performed in our CAP-accredited, CLIA-certified laboratory for clinical applications.
For a multiomics approach, this proteomics service can be combined with Azenta’s genomic and transcriptomic solutions to provide a comprehensive understanding of molecular changes contributing to development, disease, and drug response in clinical trials.
Streamline your discovery and clinical workflows with multiomics solutions you can trust.
Genomics, transcriptomics, epigenomics, and proteomics individually provide unique and crucial insight into the inner workings of human cells. Collectively, these multiomic tools can provide detailed insights into relationships and patterns to help you accelerate and expand your search for drug targets.
|Olink Explore 3072/384||Olink Target 96||Olink Target 48||Olink Flex|
|Comprised of eight 384-plex human disease focused panels, Olink Explore is both flexible and scalable; you may run the entire library or focus on one or more of the 384-plex panels.||With Olink Target 96, choose from fifteen carefully designed panels built for specific areas of human disease and key biological processes. For researchers working with mouse models, Target 96 Mouse Exploratory is also available.||One of the broadest human cytokine inflammation panels available, Olink Target 48 allows for analysis of proteins with the highest relevance for investigation of inflammatory processes and diseases to support clinical trials.||
With Olink’s made-to-order product, Olink Flex, researchers can select and combine targets for up to 21 human proteins in one biomarker panel. Choose from over 200 inflammation-related human proteins in a comprehensive mix-and-match library.
These panels are organized into four disease areas:
Use the Target 48 cytokine panel to elucidate:
Choose and combine pre-validated inflammation focused assays from Olink's extensive biomarker library. The assays have 99% combinability and maintains the quality, performance, specificity, and sensitivity associated with standard Olink panels. The data is reported in absolute (pg/mL) or relative (NPX) quantification.
Custom bioinformatics analysis and reports are available. Please contact us about how we can customize your analysis to answer your biological question.
The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics - mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) - and highlight their strengths and limitations.
Traditionally preclinical exploratory research and clinical trial biomarker detection and measurement have been restricted to a few indicators measured by mass spectrometry and ELISA. Discover how Azenta has implemented fully validated protein biomarker discovery services using the Olink® Proximity Extension Assay (PEA) technology capable of detecting and measuring hundreds to thousands of proteins simultaneously.
The development of novel strategies for mid-to high-plex protein detection and quantification enables greater utilization of protein biomarkers across the drug discovery and development process. Using Olink® Proximity Extension Assay (PEA) technology, Azenta has deployed fully validated protein biomarker discovery services for up to 1 million data points per experiment with comparable sensitivity to traditional methods and utilization of lower sample amounts.
Current proteomics technologies often present limitations in terms of throughput, specificity, and cost. However, new innovations, such as Olink Proteomics’ PEA technology, are overcoming these challenges by enabling hundreds to thousands of proteins to be measured in a single sample. In this blog, discover how Azenta is leveraging PEA technology for protein biomarker discovery, its applications, and how it can complement genomics data to accelerate drug development.
Hear directly from Olink Proteomics about precision protein analysis as a tool to improve health outcomes for patients with cancer, inflammatory, or age-related diseases. Take this chance to discover how you can bring your protein biomarker discovery to the next level with Olink PEA technology.
The -omics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexities underpinning human health. In this recording from the Azenta Life Sciences Breakfast Talk at ASHG 2022, Dr. Andrea O’Hara presents a workflow to rapidly produce a diverse set of multiomics results, including genomics, epigenomics, transcriptomics, and proteomics, from a single blood draw.
The multiomics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexity underpinning human health. Explore how the single blood draw multiomics workflow from Azenta Life Sciences can drive more significant insights and innovation in human health applications.
Azenta is a certified service provider for Illumina and other cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing only projects.